Dr. Reddy’s Laboratories Limited (RDY) Scheduled to Post Earnings on Thursday
Dr. Reddy’s Laboratories Limited (NYSE:RDY) will release its Q214 earnings data on Thursday, October 31st. Analysts expect Dr. Reddy’s Laboratories Limited to post earnings of $0.46 per share and revenue of $561.00 million for the quarter.
Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) opened at 39.83 on Wednesday. Dr. Reddy’s Laboratories Limited has a 1-year low of $29.77 and a 1-year high of $39.95. The stock’s 50-day moving average is $34.91 and its 200-day moving average is $35.7. The company has a market cap of $6.774 billion and a P/E ratio of 21.14.
RDY has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Dr. Reddy’s Laboratories Limited from an “underperform” rating to a “neutral” rating in a research note to investors on Monday, October 7th. They now have a $39.90 price target on the stock. Analysts at Jefferies Group raised their price target on shares of Dr. Reddy’s Laboratories Limited from $33.04 to $35.00 in a research note to investors on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Dr. Reddy’s Laboratories Limited presently has an average rating of “Buy” and an average price target of $37.21.
Dr. Reddy’s Laboratories Limited (NYSE:RDY) is an integrated pharmaceutical company focused on providing medicines through its three business segments: Global Generics segment, Pharmaceutical Services and Active Ingredients (PSAI) segment and Proprietary Products segment.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.